The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery.
We compared the effects of lipid lowering with rosuvastatin (RSV) monotherapy versus intensified treatment by combining RSV with ezetimibe (EZT) on kidney function in patients undergoing vascular surgery. Patients were randomly assigned to either 10 mg/d RSV (n = 136) or RSV 10 mg/d plus EZT 10 mg/d (RSV/EZT, n = 126). At 12 months, a similar decrease in estimated glomerular filtration rate (eGFR) was noted. Patients who achieved a low-density lipoprotein cholesterol (LDL-C) of <100 mg/dL had less eGFR decrease than those patients having an LDL-C limit of more than 100 mg/dL. There were no significant changes in the urinary total protein to creatinine ratio in either group. Significant microalbuminuria was evident in both the groups. Patients undergoing vascular surgery show deterioration in their renal function during the first year, despite statin therapy. Intensified lipid-lowering therapy by adding EZT does not appear to have any renoprotective effect.
Department of Surgery-Vascular Surgery Unit, School of Medicine, University of Ioannina, Ioannina, Greece.
George N
GN
Kouvelos
Department of Anesthesiology, School of Medicine, University of Ioannina, Ioannina, Greece.
Eleni M
EM
Arnaoutoglou
Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Haralampos J
HJ
Milionis
First Department of Internal Medicine, School of Medicine, University of Athens, Athens, Greece.
Vaia D
VD
Raikou
Department of Surgery-Vascular Surgery Unit, School of Medicine, University of Ioannina, Ioannina, Greece.
Nektario
N
Papa
Department of Surgery-Vascular Surgery Unit, School of Medicine, University of Ioannina, Ioannina, Greece mimats@cc.uoi.gr milmats@gmail.com.
Miltiadis I
MI
Matsagkas
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000419:Albuminuria / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D050171:Dyslipidemias / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D017558:Elective Surgical Procedures; D000069438:Ezetimibe; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006115:Greece; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000009:adverse effects
D000924:Anticholesteremic Agents; D001384:Azetidines; D015415:Biomarkers; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069438:Ezetimibe
cholesterol; estimated glomerular filtration rate; ezetimibe; kidney; rosuvastatin; surgery